{
  "@context": "http://id.who.int/icd/contexts/contextForLinearizationEntity.json",
  "@id": "http://id.who.int/icd/release/11/2024-01/mms/397276103",
  "parent": [
    "http://id.who.int/icd/release/11/2024-01/mms/804833492"
  ],
  "browserUrl": "https://icd.who.int/browse/2024-01/mms/en#397276103",
  "code": "6C42.4",
  "source": "http://id.who.int/icd/entity/397276103",
  "classKind": "category",
  "postcoordinationScale": [
    {
      "@id": "http://id.who.int/icd/release/11/2024-01/mms/397276103/postcoordinationScale/hasCausingCondition",
      "axisName": "http://id.who.int/icd/schema/hasCausingCondition",
      "requiredPostcoordination": "true",
      "allowMultipleValues": "AllowAlways",
      "scaleEntity": [
        "http://id.who.int/icd/release/11/2024-01/mms/686500513"
      ]
    }
  ],
  "title": {
    "@language": "en",
    "@value": "Synthetic cannabinoid withdrawal"
  },
  "definition": {
    "@language": "en",
    "@value": "Synthetic cannabinoid withdrawal is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of synthetic cannabinoids in individuals who have developed Synthetic cannabinoid dependence or have used synthetic cannabinoids for a prolonged period or in large amounts. Presenting features of Synthetic cannabinoid withdrawal may include irritability, anger, aggression, shakiness, insomnia and disturbing dreams, restlessness, anxiety, depressed mood and appetite disturbance. In the early phase, Synthetic cannabinoid withdrawal may be accompanied by residual features of intoxication from the drug, such as paranoid ideation and auditory and visual hallucinations."
  },
  "indexTerm": [
    {
      "label": {
        "@language": "en",
        "@value": "Synthetic cannabinoid withdrawal"
      }
    }
  ]
}